Cancer campaigner fights fresh battle for treatment

Cancer campaigner fights fresh battle for treatment Cancer campaigner fights fresh battle for treatment

A CANCER sufferer who fought a successful campaign for life-extending drugs is facing his third battle for treatment.

If Clive Stone is turned down again, he faces having to pay privately for a procedure which is routinely given to NHS patients elsewhere.

Mr Stone was diagnosed with kidney cancer in 2007.

Since then, the 63-year-old from Eynsham has fought to get access to treatment for himself and other cancer patients.

The father-of-two first took on the National Institute for Health and Clinical Excellence (Nice) to get it to approve use by the NHS of life-extending drug Sunitinib, or Sutent, as a first-line treatment for renal cancer.

He then challenged health officials again after learning his cancer had spread to his brain and he needed gamma knife radiosurgery, a procedure not routinely funded by NHS Oxfordshire.

Mr Stone said that as part of the process to decide whether he was an “exceptional case” he had to send a letter to a priorities panel explaining why he should be kept alive.

He was eventually treated but the tumours have since returned and he faces another battle to get treatment after new guidance for NHS commissioning bodies was issued.

It states that gamma knife surgery – or stereotactic radiosurgery – will only be funded for those patients who have not had it before, have no more than three tumours which are no more than 3cm (1.1in) in diameter, and must have “no evidence of active malignant disease elsewhere”.

Previously there were no formal guidelines and cases were considered individually.

Mr Stone said the guidance automatically ruled out most, if not all patients seeking the treatment.

He added: “Patients tend to get tumours in the brain as a result of having cancer elsewhere. It tends to spread to the brain last. We have been condemned to an early and very painful death by this draconian new policy.”

Mr Stone has been told his application for a second round of funding was turned down. He will now have to ask to be treated as an exceptional case again or pay himself.

In the past three years NHS Oxfordshire has received 11 requests for funding for the procedure, of which six were approved.

Mr Stone said the problem of obtaining the treatment on the NHS was not confined to Oxfordshire. In some areas the rules were even more stringent, but in Yorkshire NHS funding is pre-approved for the surgery if there are “appropriate clinical problems”.

In the past year the PCT there has approved all nine funding requests it received.

NHS Oxfordshire said that so-called metastatic spread of cancer to the brain occurred in 20 to 40 per cent of people with disseminated cancer.

A spokesman said: “Stereotactic radiosurgery for cerebral metastases which, under current policy is low priority, has been reviewed by the Milton Keynes, Oxfordshire, Berkshire East, Berkshire West and Buckinghamshire priorities committee.

“The committee’s recommendation for the use of stereotactic radiosurgery for cerebral metastases and the clinical criteria are based on a review of published evidence, current clinical practice and also take into account clinicians’ views.

“Patients who do not meet the criteria for treatment set out in the recommendation and individual requests for funding treatments not normally commissioned will always be considered.”

Mr Stone, who was awarded an MBE for his campaigning, lost his wife Jan to breast cancer last year. She was 61.

Mr Stone said: “This treatment gave me time to care for my wife here at home, thereby saving the NHS bed costs.”

He added: “I will carry on fighting for me and other cancer patients.”

Comments(2)

xjohnx says...
3:44pm Wed 6 Jun 12

I wish this gentleman well but can't honestly say thaty I agree with paying for the treatments he is fighting for.

Man on the Green says...
10:41am Fri 8 Jun 12

If we never try out new treatments to assess their efficacy, we will never learn whether they are cost effective for the NHS. This treatment is certainly viewed as promising, just as other treatments not available in this country but widely available elsewhere in Europe, such as charged particle therapy (which may well be an option that could be considered in Mr Stone's case, with authorisation being given for treatment abroad, in France, Germany or Italy, where such facilities exist). By their experimental nature, and because of medical ethics, such treatments are only ever likely to be offered at this stage of their development to people for whom other treatments have been tried and exhausted. If it can be shown that this treatment really can reach parts that other treatments can't, then that could be very good news for other people in the future. It is in no-one's interest for science to stand still, and to test such therapies, we need suitable patients.

I wish Mr Stone every luck in his request for review (and generally, of course - he has done a wonderful job campaigning for others, in the most trying of circumstances), and would certainly consider that a compelling case for exceptional grounds could be made out.

click2find

About cookies

We want you to enjoy your visit to our website. That's why we use cookies to enhance your experience. By staying on our website you agree to our use of cookies. Find out more about the cookies we use.

I agree